Tamoxifen is a nonsteroidal anti-estrogenic drug used for adjuvant treatment of breast cancer and recently as a chemopreventative agent for breast cancer and, on an investigational basis, for other cancers. To date there are case reports of hypertriglyceridemia and fatty liver disease in tamoxifen ...
Tamoxifen is a nonsteroidal anti-estrogenic drug used for adjuvant treatment of breast cancer and recently as a chemopreventative agent for breast cancer and, on an investigational basis, for other cancers. To date there are case reports of hypertriglyceridemia and fatty liver disease in tamoxifen u...
[14]. This form ofchemoprophylaxishas not been widely adopted; in the population as a whole the proportion of women who stand to benefit is low, and the risks of unnecessarydrug treatmentin the remainder have to be taken into account. In a survey in North Carolina 10% or less of women...
Tamoxifen is a nonsteroidal anti-estrogenic drug used for adjuvant treatment of breast cancer and recently as a chemopreventative agent for breast cancer and, on an investigational basis, for other cancers. To date there are case reports of hypertriglyceridemia and fatty liver disease in tamoxifen ...
Here we show for the first time, the versatile, composite effects of a new drug duo that could be an effective therapy for chemoresistant CRC and possibly other cancers, solid and hematological. Supported by NIH GM77391.doi:10.1096/fasebj.26.1_supplement.993.1Samy Morad...
concentrations, which were minimally toxic to the 3 bladder cancer cell lines used, enhanced the chemosensitivity of bladder cancer cells in most drug combinations in a dose-dependent manner. In some combinations 10 microM. tamoxifen did better than 5 microM. in chemosensitization. The effect of ...
Tamoxifen is a partial estrogen agonist in breast and thus is used as a treatment and chemopreventative for breast cancer. Tamoxifen is a full agonist in bone and endometrium, and prolonged use of tamoxifen leads to a fourfold to fivefold increase in the incidence of endometrial cancer. See Ch...
estrogen receptor-positive breast cancer. Combined therapy in the same patient group has a high cost-utility ratio compared with no therapy but quality-of-life and patient preference data suggest that the costs may be justified. Firm conclusions relating to the use of the drug in other patient ...
The clinical acceptance and validation of the therapeutic strategy of long-term adjuvant tamoxifen treatment mandated an examination of acquired drug resistance under laboratory conditions. The first model in vivo of acquired resistance of ER-positive breast cancer cells transplanted into immune deficient ...
Differentiated thyroid cancer accounts for a majority of the nearly 200,000 people in the United States with thyroid cancer. A significant minority of pati... BR Haugen - 《Semin Surg Oncol》 被引量: 82发表: 2015年 Improved disease-free survival with epirubicin-based chemoendocrine adjuvant ther...